Preserving hip bone mineral density following stroke using intravenous zoledronic acid: Findings from a 1 year randomised controlled trial

Preserving hip bone mineral density following stroke using intravenous zoledronic acid: Findings from a 1 year randomised controlled trial

Detalhes bibliográficos
Main Authors:	Poole, K, Warburton, E, Loveridge, N, Rose, C, Reeve, J
Formato:	Journal article
Publicado em:	2004

Registos relacionados

Zoledronate prevents bone loss after stroke
Por: Poole, K, et al.
Publicado em: (2006)

A single infusion of zoledronate prevents bone loss after stroke.
Por: Poole, K, et al.
Publicado em: (2007)

Single dose of zoledronate prevents bone loss after acute stroke
Por: Poole, K, et al.
Publicado em: (2006)

The effects of zoledronate on iliac bone remodelling; a histomorphometric study in stroke patients
Por: Poole, K, et al.
Publicado em: (2007)

A single injection of zoledronic acid may prevent bone loss after stroke: Planned interim analysis of a randomised trial
Por: Poole, K, et al.
Publicado em: (2004)

Bone structure and remodelling in stroke patients: early effects of zoledronate.
Por: Poole, K, et al.
Publicado em: (2009)

The effects of zoledronate on iliac bone remodelling in stroke patients
Por: Poole, K, et al.
Publicado em: (2007)

Pathophysiology of bone loss after stroke; A role for vitamin D?
Por: Poole, K, et al.
Publicado em: (2004)

FATIGUE AND OTHER SYMPTOMS FOLLOWING INTRAVENOUS ZOLEDRONATE THERAPY
Por: Warburton, S, et al.
Publicado em: (2009)

Yearly zoledronic acid in postmenopausal osteoporosis.
Por: Poole, K, et al.
Publicado em: (2007)

Bone mineralization density and femoral neck fragility.
Por: Loveridge, N, et al.
Publicado em: (2004)

Zoledronic Acid Ameliorates the Bone Turnover Activity and Periprosthetic Bone Preservation in Cementless Total Hip Arthroplasty
Por: Allen Herng Shouh Hsu, et al.
Publicado em: (2022-03-01)

Discrimination between cases of hip fracture and controls is improved by hip structural analysis compared to areal bone mineral density. An ex vivo study of the femoral neck.
Por: Mayhew, P, et al.
Publicado em: (2004)

Reduced vitamin D in acute stroke.
Por: Poole, K, et al.
Publicado em: (2006)

Denosumab versus zoledronate for the treatment of low bone mineral density in male HIV-infected patients
Por: Polyzois Makras, et al.
Publicado em: (2021-12-01)

Rapid long-term bone loss following stroke in a man with osteoporosis and atherosclerosis.
Por: Poole, K, et al.
Publicado em: (2005)

Age-related loss of trabecular bone in the femoral neck with relative preservation of the inferior region
Por: Poole, K, et al.
Publicado em: (2009)

Effect of Zoledronic Acid on Bone Mineral Density in Men with Prostate Cancer Receiving Gonadotropin-Releasing Hormone Analog
Por: Anoop Kapoor, et al.
Publicado em: (2011-01-01)

FAILURE OF P1NP SUPPRESSION FOLLOWING INTRAVENOUS ZOLEDRONATE: EFFECT OF DEFINITIONS, DOSE, VITAMIN D STATUS, AND BMI
Por: Warburton, S, et al.
Publicado em: (2009)

Effect of intravenous administration of zoledronic acid on jaw bone density in cases having skeletal metastasis: A prospective clinical study
Por: Veena Jain, et al.
Publicado em: (2019-01-01)

Changes in bone mineral density in the hip and spine before, during, and after the menopause in elite runners.
Por: Tomkinson, A, et al.
Publicado em: (2003)

Sequential treatment with zoledronic acid followed by teriparatide or vice versa increases bone mineral density and bone strength in ovariectomized rats
Por: T. Shimizu, et al.
Publicado em: (2017-12-01)

Once-yearly zoledronic acid in hip fracture prevention
Por: Oddom Demontiero, et al.
Publicado em: (2009-03-01)

A randomised controlled trial of intravenous zoledronic acid in malignant pleural disease: a proof of principle pilot study.
Por: Amelia O Clive, et al.
Publicado em: (2015-01-01)

Coxarthrosis: Protection against hip fracture is associated with decreased lacunar density and increased cancellous bone mass.
Por: Jordan, G, et al.
Publicado em: (2000)

Bone material properties and intracapsular hip fractures.
Por: Loveridge, N, et al.
Publicado em: (2000)

Bone Mineral Density in Stroke Patients
Por: Nilüfer Balcı, et al.
Publicado em: (2005-03-01)

Regional Differences in Femoral Neck Cortical Thickness Determine Hip Fragility: An in-Vivo CT Study
Por: Mayhew, P, et al.
Publicado em: (2008)

Falls, fractures, and osteoporosis after stroke: time to think about protection?
Por: Poole, K, et al.
Publicado em: (2002)

Increased bone mass but delayed mineralization: in vivo and in vitro study for zoledronate in bone regeneration
Por: Rongchang Wang, et al.
Publicado em: (2024-09-01)

Time associated with intravenous zoledronic acid administration in patients with breast or prostate cancer and bone metastasis
Por: Richhariya A, et al.
Publicado em: (2012-02-01)

(PREMIER POSTER - AWARD CANDIDATE and ALLIED HEALTH PROFESSIONAL AWARD) ASYMMETRIC FEMORAL NECK TRABECULAR BONE LOSS WITH AGEING: RELATIVE PRESERVATION OF THE INFERIOR REGION
Por: Poole, K, et al.
Publicado em: (2009)

Hyponatremia after intravenous zoledronic acid administration: A case report
Por: Nafis Vural, et al.
Publicado em: (2023-12-01)

Localised impairment of bone formation in osteoporotic hip fracture.
Por: Bell, K, et al.
Publicado em: (2000)

Discordance Between Spine-Hip and Paretic-Nonparetic Hip Bone Mineral Density in Hemiplegic Stroke Patients: A Multicenter Retrospective Study
Por: Seung Don Yoo, et al.
Publicado em: (2024-12-01)

Effect of 2 mg versus 4 mg of intravenous zoledronic acid on bone mineral density at the lumbar Spine in Indian postmenopausal women with osteoporosis: A Double-blind parallel-arm randomized controlled trial
Por: Harsh Durgia, et al.
Publicado em: (2021-01-01)

A comparison of femoral hip cortical widths and densities measured using pQCT and histomorphometry
Por: Mayhew, P, et al.
Publicado em: (2002)

Assessing Bone Mineral Density Following Acute Hip Fractures
Por: Osa Emohare MBBS, PhD, et al.
Publicado em: (2015-03-01)

Zoledronic acid in breast cancer: latest findings and interpretations
Por: Michael Gnant
Publicado em: (2011-11-01)

Intravenous zoledronate for postmenopausal women with osteopenia and osteoporosis: a systematic review and metanalysis
Por: Fernanda Martins Gazoni, et al.
Publicado em: (2023-05-01)